Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oncolytic herpes virus retargeted to HER-2.
Lollini PL, Menotti L, De Giovanni C, Campadelli-Fiume G, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Cell Cycle. 2009 Sep 15;8(18):2859-60. doi: 10.4161/cc.8.18.9368. Epub 2009 Sep 26. Cell Cycle. 2009. PMID: 19729994 No abstract available.
Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G, De Giovanni C, Gatta V, Nanni P, Lollini PL, Menotti L. Campadelli-Fiume G, et al. Among authors: de giovanni c. Rev Med Virol. 2011 Jul;21(4):213-26. doi: 10.1002/rmv.691. Epub 2011 May 27. Rev Med Virol. 2011. PMID: 21626603 Review.
The molecular basis of herpesviruses as oncolytic agents.
Menotti L, Campadelli-Fiume G, Nanni P, Lollini PL, De Giovanni C. Menotti L, et al. Among authors: de giovanni c. Curr Pharm Biotechnol. 2012 Jul;13(9):1795-803. doi: 10.2174/138920112800958931. Curr Pharm Biotechnol. 2012. PMID: 21740356 Review.
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
Nanni P, Gatta V, Menotti L, De Giovanni C, Ianzano M, Palladini A, Grosso V, Dall'ora M, Croci S, Nicoletti G, Landuzzi L, Iezzi M, Campadelli-Fiume G, Lollini PL. Nanni P, et al. Among authors: de giovanni c. PLoS Pathog. 2013 Jan;9(1):e1003155. doi: 10.1371/journal.ppat.1003155. Epub 2013 Jan 31. PLoS Pathog. 2013. PMID: 23382683 Free PMC article.
Cancer immunoprevention.
Lollini PL, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Future Oncol. 2005 Feb;1(1):57-66. doi: 10.1517/14796694.1.1.57. Future Oncol. 2005. PMID: 16555976 Review.
Immunoprevention and immunotherapy of mammary carcinoma.
Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P. Lollini PL, et al. Among authors: de giovanni c. Breast J. 2010 Sep-Oct;16 Suppl 1:S39-41. doi: 10.1111/j.1524-4741.2010.01002.x. Breast J. 2010. PMID: 21050308
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft.
Landuzzi L, Palladini A, Ceccarelli C, Asioli S, Nicoletti G, Giusti V, Ruzzi F, Ianzano ML, Scalambra L, Laranga R, Balboni T, Arigoni M, Olivero M, Calogero RA, De Giovanni C, Dall'Ora M, Di Oto E, Santini D, Foschini MP, Cucchi MC, Zanotti S, Taffurelli M, Nanni P, Lollini PL. Landuzzi L, et al. Among authors: de giovanni c. Sci Rep. 2021 Jan 15;11(1):1563. doi: 10.1038/s41598-021-81085-y. Sci Rep. 2021. PMID: 33452364 Free PMC article.
High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy.
Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL. Nanni P, et al. Among authors: de giovanni c. Eur J Cancer. 2010 Feb;46(3):659-68. doi: 10.1016/j.ejca.2009.11.018. Epub 2009 Dec 22. Eur J Cancer. 2010. PMID: 20031388
180 results